REMD Biotherapeutics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $994K

  • Investors
  • 4

REMD Biotherapeutics General Information

Description

Operator of a biopharmaceutical company intended to change and upgrade the practice of medicine. The company develops protein therapeutics to treat cancer, diabetes, and other diseases, enabling patients to have access to effective, safe, and affordable treatments.

Contact Information

Website
www.remdbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4010 Adolfo Road
  • Suite A
  • Camarillo, CA 93012
  • United States
+1 (805)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 4010 Adolfo Road
  • Suite A
  • Camarillo, CA 93012
  • United States
+1 (805)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

REMD Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Grant 01-Sep-2020 $994K Completed Clinical Trials - Phase 2
5. Grant 16-Sep-2019 Completed Clinical Trials - Phase 2
4. Later Stage VC 20-Nov-2017 Completed Clinical Trials - Phase 2
3. Later Stage VC 27-Jul-2017 Completed Clinical Trials - Phase 2
2. Grant 01-Jul-2017 $1.43M Completed Startup
1. Grant 01-Sep-2016 $225K Completed Startup
To view REMD Biotherapeutics’s complete valuation and funding history, request access »

REMD Biotherapeutics Patents

REMD Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025178928-A1 Combination therapy for the treatment of obesity Pending 23-Feb-2024
WO-2025178928-A9 Combination therapy for the treatment of obesity Pending 23-Feb-2024
EP-4594363-A1 C-c chemokine receptor type 8 (ccr8) antagonist antibodies Pending 02-Oct-2022
EP-4594363-A4 C-c chemokine receptor type 8 (ccr8) antagonist antibodies Pending 02-Oct-2022
US-20260109770-A1 C-c chemokine receptor type 8 (ccr8) antagonist antibodies Pending 02-Oct-2022 C07K16/2866
To view REMD Biotherapeutics’s complete patent history, request access »

REMD Biotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

REMD Biotherapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Institute of Diabetes and Digestive and Kidney Diseases Government
Jiuzhitang Corporation Minority
Shenzhen Naland Investment Fund Management Growth/Expansion Minority
U.S. Department of Health and Human Services Government
To view REMD Biotherapeutics’s complete investors history, request access »

REMD Biotherapeutics FAQs

  • When was REMD Biotherapeutics founded?

    REMD Biotherapeutics was founded in 2011.

  • Where is REMD Biotherapeutics headquartered?

    REMD Biotherapeutics is headquartered in Camarillo, CA.

  • What is the size of REMD Biotherapeutics?

    REMD Biotherapeutics has 8 total employees.

  • What industry is REMD Biotherapeutics in?

    REMD Biotherapeutics’s primary industry is Drug Discovery.

  • Is REMD Biotherapeutics a private or public company?

    REMD Biotherapeutics is a Private company.

  • What is REMD Biotherapeutics’s current revenue?

    The current revenue for REMD Biotherapeutics is .

  • How much funding has REMD Biotherapeutics raised over time?

    REMD Biotherapeutics has raised $30.1M.

  • Who are REMD Biotherapeutics’s investors?

    National Institute of Diabetes and Digestive and Kidney Diseases, Jiuzhitang, Shenzhen Naland Investment Fund Management, and U.S. Department of Health and Human Services have invested in REMD Biotherapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process